6,015 Shares in Lantheus Holdings, Inc. $LNTH Bought by Centaurus Financial Inc.

Centaurus Financial Inc. bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, HoldingsChannel reports. The institutional investor bought 6,015 shares of the medical equipment provider’s stock, valued at approximately $667,000.

A number of other institutional investors and hedge funds have also made changes to their positions in LNTH. Farallon Capital Management LLC grew its position in Lantheus by 56.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after buying an additional 1,950,252 shares during the period. Jupiter Topco LLC purchased a new stake in shares of Lantheus during the 2nd quarter worth approximately $575,628,000. Reinhart Partners LLC. grew its holdings in shares of Lantheus by 2.2% in the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after acquiring an additional 34,501 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Lantheus by 3.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after acquiring an additional 44,374 shares during the period. Finally, Carmignac Gestion increased its stake in Lantheus by 18.4% in the 1st quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock valued at $100,729,000 after purchasing an additional 206,000 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Up 0.3%

Shares of NASDAQ:LNTH opened at $100.77 on Friday. Lantheus Holdings, Inc. has a 52-week low of $49.67 and a 52-week high of $111.86. The company has a market capitalization of $6.58 billion, a P/E ratio of 24.34 and a beta of -0.03. The stock’s fifty day simple moving average is $103.74 and its 200-day simple moving average is $91.58. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The business had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.57 earnings per share. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on LNTH. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. William Blair set a $102.50 price objective on shares of Lantheus in a research report on Monday, August 3rd. B. Riley Financial cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Finally, Citizens Jmp restated a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a report on Monday, June 29th. Four investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, Lantheus currently has a consensus rating of “Hold” and an average target price of $108.11.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.